A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence.

Robert A SchnollFrank LeoneAnna Veluz-WilkinsAndrew MieleAnita HoleNancy C JaoE Paul WileytoAllison J CarrollRavi KalhanJyoti PatelCorey LangerSu Fen LubitzBrian Hitsman

Published in: Psycho-oncology (2019)

Compared with ST, ET varenicline does not increase patient risk and increases smoking cessation rates among patients who adhere to treatment. Studies are needed to identify effective methods to increase medication adherence to treat patient tobacco use effectively.

Keyphrases

smoking cessation
replacement therapy
case report
metabolic syndrome
skeletal muscle
glycemic control